Alembic Pharma share price gains as associate company enters agreement to develop Tenalisib

Rhizen Pharmaceuticals announced that it has entered into an exclusive license agreement with Curon Biopharmaceutical Limited. Alembic Pharmaceuticals through its wholly owned subsidiary holds 50 percent ownership in Rhizen.

Read Full Story on MoneyControl

Enter your email address:


We will be happy to hear your thoughts

      Leave a reply

      IndiaClicking - Buzzing News & Stocks